Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on New Jersey Health Reporter.
Press releases published on July 22, 2025
SciSparc Ltd. Regains Compliance with Nasdaq Minimum Bid Price Notification
GlobeNewswire
·
July 22, 2025
Tel Aviv, July 22, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (“SciSparc” or the “Company”) (Nasdaq: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous …
Beyond Air Awarded Therapeutic Gases Agreement with Premier, Inc.
GlobeNewswire
·
July 22, 2025
GARDEN CITY, N.Y., July 22, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives …
Rezolute to Participate in the BTIG Virtual Biotechnology Conference
GlobeNewswire
·
July 22, 2025
REDWOOD CITY, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism, today announced that management will …
BridgeBio to Host Second Quarter 2025 Financial Results Conference Call on Tuesday, August 5, 2025 at 4:30 pm ET
GlobeNewswire
·
July 22, 2025
PALO ALTO, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that it will release its second quarter …
Reunion Neuroscience Announces Publication of RE104 Phase 1 Data in The Journal of Clinical Psychopharmacology
GlobeNewswire
·
July 22, 2025
-- Phase 1 Data Highlight RE104 Favorable Safety Profile and Short Duration Psychoactive Experience -- -- Topline Results from RECONNECT Phase 2 Trial of RE104 in Postpartum Depression (PPD) Anticipated in Q3 2025 -- MORRISTOWN, N.J., July 22, 2025 (GLOBE …
Arch Biopartners Announces Start of Patient Recruitment in Phase II PONTIAK Trial Targeting Drug-Toxin-Related Acute Kidney Injury (AKI)
GlobeNewswire
·
July 22, 2025
TORONTO, July 22, 2025 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that the investigator-led Phase II trial titled “Prevention Of NephroToxin Induced Acute Kidney Injury with …
CMMB Introduces Derek Yach as New Global Health Advisor
GlobeNewswire
·
July 22, 2025
New York, New York, July 22, 2025 (GLOBE NEWSWIRE) -- Catholic Medical Mission Board (CMMB) is thrilled to announce the appointment of public health expert Derek Yach as its new global health advisor for noncommunicable diseases (NCDs) and therapeutics. …
uniQure to Announce Second Quarter 2025 Financial Results
GlobeNewswire
·
July 22, 2025
LEXINGTON, Mass. and AMSTERDAM, July 22, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs will report second quarter 2025 financial results before …
Seres Therapeutics to Announce Second Quarter 2025 Financial Results and Business Updates on August 6, 2025
GlobeNewswire
·
July 22, 2025
CAMBRIDGE, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will host a conference call and live audio webcast on August 6, 2025 at 8:30 a.m. ET to …
ProMIS Neurosciences Announces Private Placement Financing
GlobeNewswire
·
July 22, 2025
TORONTO, Ontario and CAMBRIDGE, Massachusetts, July 22, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company committed to discovery and development of therapeutic antibodies targeting toxic misfolded …
Health Canada Authorizes bioLytical’s iStatis Syphilis Test, Boosting Rapid Response to Rising Infections in Canada
GlobeNewswire
·
July 22, 2025
Now authorized for professional use in Canada, the iStatis Syphilis Antibody Test offers a fast, accurate, and portable solution to strengthen syphilis screening efforts nationwide. Health Canada authorizes the iStatis Syphilis Antibody Test for …
Santé Canada autorise le test de dépistage de la syphilis iStatis de bioLytical, afin de renforcer la réponse rapide à l’augmentation des infections au Canada
GlobeNewswire
·
July 22, 2025
Maintenant autorisé à une utilisation professionnelle au Canada, le test de dépistage des anticorps de la syphilis iStatis offre une solution rapide, précise et portable pour renforcer les efforts de dépistage de la syphilis dans tout le pays. Santé Canada …
Memo Therapeutics AG Publishes Study on its Potent Antibody for Treatment of BKPyV Infection in Kidney Transplantation
GlobeNewswire
·
July 22, 2025
PRESS RELEASE Memo Therapeutics AG Publishes Study on its Potent Antibody for Treatment of BKPyV Infection in Kidney Transplantation Novel antibody, potravitug, demonstrates high neutralization of all BKPyV serotypes with potential to transform treatment …
Tango Therapeutics to Report Second Quarter 2025 Financial Results on Tuesday, August 5, 2025
GlobeNewswire
·
July 22, 2025
BOSTON, July 22, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that it will report second quarter 2025 financial results on August 5, 2025, before the open of the U.S. financial markets. The company does not intend to …
InspireMD to Announce Second Quarter 2025 Financial Results
GlobeNewswire
·
July 22, 2025
MIAMI, Fla., July 22, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced that it will release its second quarter 2025 financial results on Tuesday, …
Avalyn Completes Oversubscribed $100 Million Series D Financing to Further Advance Clinical Development of Novel Inhaled Therapies for Pulmonary Fibrosis
GlobeNewswire
·
July 22, 2025
Financing led by Suvretta Capital Management and SR One with participation from 16 additional healthcare investors Proceeds will support key clinical milestones across all of Avalyn’s pipeline programs CAMBRIDGE, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- …
Morphoceuticals Announces Roger Pomerantz, MD, as Chairman of its Board of Directors
GlobeNewswire
·
July 22, 2025
MEDFORD, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Morphoceuticals Inc., a TechBio company pioneering AI-guided electroceuticals for tissue repair and organ regeneration, today announced the appointment of industry veteran Roger Pomerantz, MD, as Chairman …
Aquestive Therapeutics Names Sherry Korczynski as Chief Commercial Officer
GlobeNewswire
·
July 22, 2025
WARREN, N.J., July 22, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and …
Ocular Therapeutix™ to Participate in Upcoming Scientific Conferences
GlobeNewswire
·
July 22, 2025
BEDFORD, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming scientific conferences in July …
OncoC4 Doses First Patient with Potential Best-in-Class PD-1/VEGF Bispecific Antibody AI-081 in Phase 2 Portion of BIPAVE-001 Trial for Advanced Solid Tumors in US
GlobeNewswire
·
July 22, 2025
ROCKVILLE, Md., July 22, 2025 (GLOBE NEWSWIRE) -- OncoC4, Inc., a late-stage biopharmaceutical company developing novel medicines for cancer today announced the first patient has been dosed in the Phase 2 portion of the Phase 1/2 BIPAVE-001 trial ( …